Fortrea Holdings Inc.
FTREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The $1.68B market capitalization puts FTRE squarely in small-cap range for its industry. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Market Cap
$1.68B
Beta
1.95
P/E (TTM)
—
P/E (Fwd)
15.55
EPS (TTM)
$-0.83
EPS (Fwd)
$1.14
ROE
-15.3%
ROA
0.6%
Cash
$168.6M
Total Debt
$1.12B
Free CF
$278.9M
52W Change
75.8%
Annual Financials
Cash vs Debt
Where FTRE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FTRE finished 28.66% above its 150-day moving average ($14.27) and 26.27% above its 200-day moving average ($14.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FTRE overbought or oversold?
At the September 3, 2026 close, FTRE's RSI(14) was 55.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $168.6M in cash, though total debt stands at $1.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $278.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -15.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.6% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.06B to $2.72B.
A beta of 1.95 means FTRE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Fortrea Holdings Inc.'s trajectory.